Analysis of the relationship between the expression profile of SMYD2 and the clinicopathological characteristics of LUAD patients from the TCGA and GEO databases showed no obvious difference between the high- and low-SMYD2 groups in age, gender, smoking status, tumor node metastasis (TNM) stage, T stage, and N stage (Tables S4–S6). Here, SMYD2 is linked to neoplasm.